Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MDK | P21741 | 3/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16359449 | 0.94 | MAPK1 (0.52) | MAPK1MDKLGALS3MEN1KMT2A | |
| SCHEMBL13671600 | 0.93 | MDK (0.43) | MAPK1MDKLGALS3MEN1KMT2A | |
| SCHEMBL24792570 | 0.89 | MAPK1 (0.46) | MAPK1MDKLGALS3MEN1KMT2A | |
| SCHEMBL10229987 | 0.87 | MAPK1 (0.53) | MAPK1MDKLGALS3MEN1KMT2A | |
| SCHEMBL21189935 | 0.87 | MAPK1 (0.53) | MAPK1MDKLGALS3MEN1KMT2A | |
| SCHEMBL16359487 | 0.86 | MDK (0.45) | MAPK1MDKLGALS3MEN1KMT2A | |
| SCHEMBL16358004 | 0.86 | MAPK1 (0.51) | MAPK1MDKLGALS3MEN1KMT2A | |
| SCHEMBL26187782 | 0.86 | MAPK1 (0.53) | MAPK1MDKLGALS3MEN1KMT2A | |
| SCHEMBL18972884 | 0.85 | MAPK1 (0.53) | MAPK1MDKLGALS3MEN1KMT2A | |
| SCHEMBL23322820 | 0.85 | MAPK1 (0.51) | MAPK1MDKLGALS3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009126933-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |